SCHEMBL15035698

SCHEMBL15035698

CCC(CC)c1cc2cnc(Nc3ccc(OC4CCN(C)CC4)cc3)nc2n(Cc2cncn2S(=O)(=O)C2CCCC2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.45
FGFR4 P22455 2/20 0.42
CDK2 P24941 5/20 0.38
CCNA2 P20248 4/20 0.38
AURKA O14965 2/20 0.38
TTK P33981 1/20 0.38
SRC P12931 1/20 0.38
TNK2 Q07912 1/20 0.38
AXL P30530 4/20 0.36
WEE1 P30291 2/20 0.36
CDK4 P11802 4/20 0.36
CCND1 P24385 4/20 0.36
FGFR1 P11362 2/20 0.36
FGFR2 P21802 1/20 0.36
FGFR3 P22607 1/20 0.36
RIPK2 O43353 2/20 0.36
NOD2 Q9HC29 2/20 0.36
ACVR1 Q04771 1/20 0.36
CCNA1 P78396 1/20 0.36
PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035047 0.85 CAMK2D (0.45) CAMK2DCDK2CCNA2AURKATTK
SCHEMBL15034832 0.80 CAMK2D (0.44) CAMK2DCDK2CCNA2AURKATTK
SCHEMBL15035934 0.79 JAK3 (0.42) FGFR4CDK2CCNA2TNK2WEE1
SCHEMBL15034942 0.79 CAMK2D (0.46) CAMK2DCDK2CCNA2AURKATTK
SCHEMBL15035819 0.78 CAMK2D (0.42) CAMK2DCDK2CCNA2AURKATTK
SCHEMBL15035911 0.77 CAMK2D (0.45) CAMK2DCDK2CCNA2AURKATTK
SCHEMBL15035800 0.73 TNK2 (0.45) CAMK2DSRCTNK2RIPK2NOD2
SCHEMBL15035671 0.72 TNK2 (0.49) SRCTNK2
SCHEMBL15035359 0.72 CAMK2D (0.44) CAMK2DFGFR4CDK2CCNA2AURKA
SCHEMBL15035566 0.71 CAMK2D (0.45) CAMK2DCDK2CCNA2AURKATTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK6 CAMK2D 146/4885FGFR4 2162/4885CDK2 211/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CAMK2D 469/4885FGFR4 1949/4885CDK2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.